Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety

Fig. 3

Binding studies of IRDye800CW-nimotuzumab with A-431 cells. Unlabeled nimotuzumab and four batches of IRDye800CW-nimotuzumab were tested for binding to the EGFR positive cell line A-431 using flow cytometry to test reproducibility of batch formulation. a and b show IRDye800CW-nimotuzumab binding compared to unlabeled nimotuzumab. c Batch-to-batch variability of IRDye800CW-nimotuzumab in cell binding. The error bars represent the standard deviation

Back to article page